Generic Name: Amlodipine Besilate BP 5mg & Olmesartan Medoxomil INN 20mg
Therapeutic Class: Combined antihypertensive preparations
Indication: Bazoka is a fixed dose & well tolerated combination of Amlodipine BP 5mg & Olmesartan Medoxomil INN 20 mg . Amlodipine is a long acting Calcium Channel Blocker (CCB) & Olmesartan is Angiotensin receptor blocker which blocks the vasoconstrictor effects of angiotensin II to AT1 receptor in vascular smooth muscle. Bazoka is widely used as first line therapy for the management of Hypertension with Angina. It is also indicated for the treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. This combination drug is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals. The decision to use a combination as initial therapy should be individualized and shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk.
Dosage & Administration: Substitute individually titrated components for patients on Amlodipine and Olmesartan Medoxomil. This combination may also be given with increased amounts of Amlodipine, Olmesartan Medoxomil, or both, as needed.
Initial therapy: Initiate with 5/20 mg once daily for 1 to 2 weeks and titrate as needed up to a maximum of 10/40 mg once daily. Due to decreased clearance of Amlodipine among elderly patients the recommended starting dose of Amlodipine is 2.5 mg in patients 75 years. The lowest dose of the combination is 5/20 mg; therefore, initial therapy with this combination drug is not recommended in patients >75 years old.
Preparation: Each box contains 30 tablets
